Blood Test Combining cfDNA Fragmentomics and Methylation Markers Detects Precancerous Lesions

▪ SCREENING

A study of 380 CRC patients, 121 individuals with precancerous lesions, and 506 healthy controls found that adding methylation analysis of SEPT9 and HS3ST2 to cfDNA fragmentomic features improved detection of precancerous lesions, a key limitation of blood-based screening. (The ASCO Post)